GOLM1 as a Potential Therapeutic Target Modulates B7-H3 Secretion to Drive Ovarian Cancer Metastasis

Figure 5

GOLM1 regulates ovarian cancer progression in vivo. (a) In vivo bioluminescence imaging of 107 GOLM1 and B7-H3 knockdown SKOV3 cell lines subcutaneous injected behind the right upper limb in immunodeficient NSG mice, using original SKOV3 as the control. Each group contains three mice. The imaging was performed at day 0 and day 42. (b) Statistics of BLI signal between three groups (). (c) Vernier caliper measurement of tumor volume every 7 days after tumor inoculation. Statistical difference was calculated at day 42 (1). (d) ELISA assay of soluble B7-H3 in peripheral blood of each mouse at day 42 (). (e) In vivo bioluminescence imaging of 107 GOLM1 and B7-H3 knockdown SKOV3 cell lines’ tail vein injected in immunodeficient NSG mice, using original SKOV3 as the control. Each group contains three mice. The imaging was performed at day 1 and day 42. (f) Statistics of BLI signal between the three groups (). (g) ELISA assay of soluble B7-H3 in peripheral blood of each mice at day 42 (). (h) Survival curve of the mice in the three groups.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)